Home
Search

Press Releases

Get the latest on BIO’s announcements, positions, and views.

Featured Press Releases
BIO Statement on the Section 232 Pharmaceutical…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on Section 232 Pharmaceutical Proclamation.“A thriving American biotechnology ecosystem is essential to…
Learn more
BIO Statement on Passage of Legislation…
WASHINGTON, D.C. - Brad Zakes, senior vice president for emerging companies and economic affairs at the Biotechnology Innovation Organization (BIO), released the following statement on passage of legislation reauthorizing the SBIR/STTR program:"The…
Learn more
Announcing Investor Connect Plus: A LaunchBio x…
Accelerating Growth Through ConnectionsLaunchBio and the Biotechnology Innovation Organization (BIO) today announced the launch of Investor Connect Plus, an exclusive, BIO member-only investor access program designed for established, capital-ready…
Learn more
All Press Releases
  • Show All
Search
Results
Event Tags
Salmon Labeling Provision Likely to Confuse Consumers, Impede Innovation
December 17, 2019
Washington, D.C. (December 17, 2019) – A rider to the FY2020 Agriculture Appropriations Bill will direct the bioengineered AquAdvantage salmon to carry additional labeling to distinguish it from conventionally raised Atlantic salmon. This could be…
Senate Confirms Dr. Hahn to Lead the Food and Drug Administration
December 12, 2019
Former Congressman Jim Greenwood, President and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement after the U.S. Senate confirmed Dr. Stephen Hahn to serve as the next commissioner of the Food and Drug…
BIO’s Jim Greenwood on H.R. 3: “Let’s Move Past This Extreme, Partisan Bill”
December 12, 2019
Trump Administration and Speaker Pelosi Surrender Powerful Tool for Reining in Foreign Free Riding
December 10, 2019
Exclusion of biologics provisions in revised USMCA sets dangerous precedent for future trade talks, including with China Puts American jobs, intellectual property and leadership in medical innovation at risk WASHINGTON – BIO President and CEO Jim…
More than 135 Emerging Biotech Leaders Urge Congress to Reject H.R. 3
December 5, 2019
More than 135 Emerging Biotech Leaders Urge Congress to Reject H.R. 3  “Our continued success depends on maintaining an environment that supports investment in tomorrow’s discoveries.” Washington, DC: December 5, 2019 – In a letter addressed…
Speaker Pelosi’s Drug Pricing Plan Could Result in 56 Fewer New Medicines Over 10 Years
November 21, 2019
Washington, D.C. (November 21, 2019) — Speaker Nancy Pelosi’s Lower Drug Costs Now Act of 2019, H.R.3, could result in at least 56 fewer new medicines for patients over 10 years, according to a new analysis from economic…
Green Energy Solutions Unleashed Through New Partnership
November 21, 2019
Washington, D.C. (November 21, 2019) – Today, the Biotechnology Innovation Organization and the Low Carbon Fuels Coalition (LCFC) announced a new joint initiative to drive adoption of low carbon fuel policies in states. Both groups will work…
America’s Bioeconomy Plays Critical Role in Feeding, Fueling, and Healing the World
October 22, 2019
“What has set the U.S. biotech sector apart has been thoughtful, bipartisan public policy approaches that create a favorable climate in which to undertake the lengthy and risky job of investing in and developing the next biotech breakthroughs.”
Proposed CFIUS Regulations Threaten Investment in America’s Life Sciences
October 21, 2019
“BIO fully supports the role of CFIUS in ensuring appropriate national security screening of certain foreign investments, but any rules must not discourage the entrepreneurial spirit that has made America the global leader in biopharmaceutical…
Nonpartisan Budget Experts Warn Speaker Pelosi’s Drug Pricing Bill will Stifle the Development of New Medicines
October 14, 2019
BIO’s President and CEO Jim Greenwood issued the following statement after the Congressional Budget Office released an analysis confirming that H.R. 3 will lead to fewer new medicines for patients.